Results 181 to 190 of about 678,841 (321)

Statistical process control to monitor use of a web‐based autoplanning tool

open access: yesJournal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Purpose To investigate the use of statistical process control (SPC) for quality assurance of an integrated web‐based autoplanning tool, Radiation Planning Assistant (RPA). Methods Automatically generated plans were downloaded and imported into two treatment planning systems (TPSs), RayStation and Eclipse, in which they were recalculated using ...
Hunter Mehrens   +5 more
wiley   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu   +11 more
wiley   +1 more source

Treatment planning with a 2.5 MV photon beam for radiation therapy

open access: yesJournal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Purpose The shallow depth of maximum dose and higher dose fall‐off gradient of a 2.5 MV beam along the central axis that is available for imaging on linear accelerators is investigated for treatment of shallow tumors and sparing the organs at risk (OARs) beyond it.
Navid Khaledi   +5 more
wiley   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

open access: yesMolecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen   +12 more
wiley   +1 more source

Volume staging for arteriovenous malformation SRS treatment using VMAT

open access: yesJournal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Volume staging involves dividing the target volume into smaller parts and treating each part separately. In this study, the feasibility of volume‐staged stereotactic radiosurgery (VS‐SRS) on a linear accelerator using volumetric modulated arc therapy (VMAT) and a frameless patient positioning system is investigated.
Claudia Mendez, Ermias Gete
wiley   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

open access: yesMolecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu   +12 more
wiley   +1 more source

Validation of pencil beam scanning proton therapy with multi‐leaf collimator calculated by a commercial Monte Carlo dose engine

open access: yesJournal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract This study aimed to evaluate the clinical beam commissioning results and lateral penumbra characteristics of our new pencil beam scanning (PBS) proton therapy using a multi‐leaf collimator (MLC) calculated by use of a commercial Monte Carlo dose engine.
Yuki Tominaga   +5 more
wiley   +1 more source

Impact of age, HIV1, sickle-cell genotypes, and interferon-gamma gene upstream variants on malaria disease outcomes in a longitudinal pediatric cohort. [PDF]

open access: yesSci Rep
Raballah E   +12 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy